documented the therapeutic advantages of FGF21 in addressing obesity‐induced hyperglycemia, hypertriglyceridemia, and peripheral IR by activating its downstream mediator, adiponectin. Here, ADIPOQ is linked to obesity due to melanocortin 4 receptor deficiency.